MX2018001979A - (s,e) -3- (6-aminopiridin-3-il) -n- ( (5- (4- (3-fluoruro-3 metilpirrolidin-1-carbonil) fenil) -7- (4 fluorofenil) benzofuran-2-il)metil)acrilamida para el tratamiento del cancer. - Google Patents
(s,e) -3- (6-aminopiridin-3-il) -n- ( (5- (4- (3-fluoruro-3 metilpirrolidin-1-carbonil) fenil) -7- (4 fluorofenil) benzofuran-2-il)metil)acrilamida para el tratamiento del cancer.Info
- Publication number
- MX2018001979A MX2018001979A MX2018001979A MX2018001979A MX2018001979A MX 2018001979 A MX2018001979 A MX 2018001979A MX 2018001979 A MX2018001979 A MX 2018001979A MX 2018001979 A MX2018001979 A MX 2018001979A MX 2018001979 A MX2018001979 A MX 2018001979A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- cancer
- treatment
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La invención se refiere generalmente a compuestos de benzofuranilo substituido, y, más en particular, a un compuesto representado por la Fórmula Estructural Ia: (ver formula) o una sal farmacéuticamente aceptable del mismo. La invención también incluye la síntesis y uso del compuesto de Fórmula Estructural Ia, o una sal farmacéuticamente aceptable del mismo, por ejemplo en el tratamiento de enfermedades o trastornos seleccionados del cáncer (por ejemplo, linfoma, tal como linfoma de célula de manto), una enfermedad neurodegenerativa, un trastorno inflamatorio o un trastorno del sistema inmune (por ej., una enfermedad autoinmune mediada por la célula T) en un sujeto en necesidad de ello. El método comprende administrar a un sujeto en necesidad de lo mismo una cantidad terapéuticamente efectiva de un compuesto de la invención, o una sal farmacéuticamente aceptable del mismo, o una composición que comprende un compuesto de la invención, o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562206472P | 2015-08-18 | 2015-08-18 | |
PCT/US2016/047566 WO2017031323A1 (en) | 2015-08-18 | 2016-08-18 | (s,e)-3-(6-aminopyridin-3-yl)-n-((5-(4-(3-fluoro-3-methylpyrrolidine-1-carbonyl)phenyl)-7-(4-fluorophenyl)benzofuran-2-yl)methyl)acrylamide for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018001979A true MX2018001979A (es) | 2019-04-25 |
Family
ID=56799634
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018001979A MX2018001979A (es) | 2015-08-18 | 2016-08-18 | (s,e) -3- (6-aminopiridin-3-il) -n- ( (5- (4- (3-fluoruro-3 metilpirrolidin-1-carbonil) fenil) -7- (4 fluorofenil) benzofuran-2-il)metil)acrilamida para el tratamiento del cancer. |
Country Status (12)
Country | Link |
---|---|
US (1) | US10363247B2 (es) |
EP (1) | EP3337797A1 (es) |
JP (1) | JP2018528196A (es) |
CN (1) | CN108137563A (es) |
AU (1) | AU2016308829A1 (es) |
CA (1) | CA2995380A1 (es) |
EA (1) | EA201890524A1 (es) |
HK (1) | HK1255438A1 (es) |
IL (1) | IL257422A (es) |
MA (1) | MA42655A (es) |
MX (1) | MX2018001979A (es) |
WO (1) | WO2017031323A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3016946T3 (da) | 2013-07-03 | 2023-01-09 | Karyopharm Therapeutics Inc | Substituerede benzofuranyl- og benzoxazolylforbindelser og anvendelser deraf |
WO2015042414A1 (en) | 2013-09-20 | 2015-03-26 | Karyopharm Therapeutics Inc. | Multicyclic compounds and methods of using same |
MA42655A (fr) | 2015-08-18 | 2021-04-07 | Karyopharm Therapeutics Inc | Acrylamide de (s,e)-3-(6-aminopyridin-3-yl)-n-((5-(4-(3-fluoro-3-méthylpyrrolidine-1-carbonyl)phényl)-7-(4-fluorophényl)benzofuran-2-yl)méthyl) pour le traitement du cancer |
WO2017117447A1 (en) | 2015-12-31 | 2017-07-06 | Karyopharm Therapeutics Inc. | Multicyclic compounds and uses thereof |
CN111171233B (zh) * | 2020-01-17 | 2023-03-31 | 吉林师范大学 | 一种新型磁性薄层印迹膜的制备方法及用途 |
CN115569133B (zh) * | 2020-02-26 | 2024-04-26 | 上海科技大学 | 甲异靛在抗冠状病毒中的应用 |
CN114507215A (zh) * | 2020-11-14 | 2022-05-17 | 成都海博为药业有限公司 | 一种作为pak4激酶抑制剂的化合物及其制备方法和应用 |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19624659A1 (de) | 1996-06-20 | 1998-01-08 | Klinge Co Chem Pharm Fab | Neue Pyridylalken- und Pyridylalkinsäureamide |
DE19624668A1 (de) | 1996-06-20 | 1998-02-19 | Klinge Co Chem Pharm Fab | Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden |
DE19818044A1 (de) | 1998-04-22 | 1999-10-28 | Klinge Co Chem Pharm Fab | Verwendung von Vitamin-PP-Verbindungen |
EA007392B1 (ru) | 2001-07-19 | 2006-10-27 | Фармация Италия С.П.А. | Фенилацетамидотиазольные производные, способ их получения и их использования в качестве противоопухолевых средств |
EP1348434A1 (en) | 2002-03-27 | 2003-10-01 | Fujisawa Deutschland GmbH | Use of pyridyl amides as inhibitors of angiogenesis |
US8450302B2 (en) | 2002-08-02 | 2013-05-28 | Ab Science | 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors |
US7078419B2 (en) | 2003-03-10 | 2006-07-18 | Boehringer Ingelheim Pharmaceuticals, Inc. | Cytokine inhibitors |
US7638540B2 (en) | 2003-05-29 | 2009-12-29 | The New Industry Research Organization | Benzofuran compound and medicinal composition containing the same |
EP1654245A1 (en) | 2003-08-07 | 2006-05-10 | Bayer Pharmaceuticals Corporation | Benzofuran derivatives useful for treating hyper-proliferative disorders |
GB2427405A (en) | 2004-04-07 | 2006-12-27 | Pharmacyclics Inc | Novel hydroxamates as therapeutic agents |
US7667041B2 (en) | 2004-05-26 | 2010-02-23 | Eisai R&D Management Co., Ltd. | Cinnamide compound |
TW200616613A (en) | 2004-10-05 | 2006-06-01 | Shionogi & Co | Biaryl derivatives |
US8084492B2 (en) | 2004-11-19 | 2011-12-27 | The New Industry Research Organization | Benzofuran compound and pharmaceutical composition containing the same |
MX2007012448A (es) | 2005-04-06 | 2007-10-19 | Astrazeneca Ab | Heterociclos sustituidos y su uso como inhibidores de chk1, pdk1 y pak. |
BRPI0609988A2 (pt) | 2005-04-22 | 2010-05-18 | Wyeth Corp | derivados de diidrobenzofurano e usos dos mesmos |
US20080020413A1 (en) | 2006-03-29 | 2008-01-24 | Columbia University | Crystalline visfatin and methods therefor |
WO2008026018A1 (en) | 2006-09-01 | 2008-03-06 | Topotarget Switzerland Sa | New method for the treatment of inflammatory diseases |
EP2003118A1 (de) | 2007-06-13 | 2008-12-17 | Bayer Schering Pharma Aktiengesellschaft | Zimtsäurederivate als Modulatoren des EP2-Rezeptors |
US8211912B2 (en) | 2007-09-26 | 2012-07-03 | Gemin X Pharmaceuticals Canada | Compositions and methods for effecting NAD+ levels using a nicotinamide phosphoribosyl tranferase inhibitor |
US8173677B2 (en) | 2007-09-26 | 2012-05-08 | Gemin X Pharmaceuticals Canada Inc. | Compositions and methods for effecting NAD+ levels using a nicotinamide phosphoribosyl transferase inhibitor |
EP2098231A1 (en) | 2008-03-05 | 2009-09-09 | Topotarget Switzerland SA | Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury |
FR2943669B1 (fr) | 2009-03-24 | 2011-05-06 | Sanofi Aventis | Derives de nicotinamide,leur preparation et leur application en therapeutique |
US20130317027A1 (en) | 2010-03-01 | 2013-11-28 | Myrexis, Inc. | Compounds and therapeutic uses thereof |
US8912184B1 (en) | 2010-03-01 | 2014-12-16 | Alzheimer's Institute Of America, Inc. | Therapeutic and diagnostic methods |
KR20130044382A (ko) | 2010-03-01 | 2013-05-02 | 마이렉시스 인코포레이티드 | 화합물 및 그의 치료 용도 |
RU2017112522A (ru) | 2011-05-04 | 2019-01-24 | ФОРМА ТиЭм, ЭлЭлСИ | Новые соединения и композиции для ингибирования nampt |
EP2739144A4 (en) | 2011-06-20 | 2015-04-01 | Alzheimer S Inst Of America Inc | COMPOUNDS AND ITS THERAPEUTIC USE |
WO2013082150A1 (en) | 2011-11-30 | 2013-06-06 | The Curators Of The University Of Missouri | Small molecule inhibitors of nicotinamide phosphoribosyltransferase (nampt) |
WO2014074715A1 (en) | 2012-11-07 | 2014-05-15 | Genentech, Inc. | Cyclopropyl amide derivatives |
US9938258B2 (en) | 2012-11-29 | 2018-04-10 | Karyopharm Therapeutics Inc. | Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof |
WO2014111871A1 (en) | 2013-01-17 | 2014-07-24 | Aurigene Discovery Technologies Limited | 4,5-dihydroisoxazole derivatives as nampt inhibitors |
DK3016946T3 (da) * | 2013-07-03 | 2023-01-09 | Karyopharm Therapeutics Inc | Substituerede benzofuranyl- og benzoxazolylforbindelser og anvendelser deraf |
WO2015042414A1 (en) | 2013-09-20 | 2015-03-26 | Karyopharm Therapeutics Inc. | Multicyclic compounds and methods of using same |
CN105579449A (zh) | 2013-10-09 | 2016-05-11 | 伊莱利利公司 | 新的用作nampt抑制剂的吡啶基氧基乙酰基四氢异喹啉化合物 |
US20170369470A1 (en) | 2014-12-16 | 2017-12-28 | Karyopharm Therapeutics Inc. | Cyclic Compounds and Uses Thereof |
WO2017031204A1 (en) | 2015-08-17 | 2017-02-23 | Karyopharm Therapeutics Inc. | Cyclopropylderivatives and their use as kinase inhibitors |
MA42654A (fr) | 2015-08-17 | 2018-06-27 | Karyopharm Therapeutics Inc | Dérivés 3-(pyridin-3-yl)-acrylamide et n-(pyridin-3-yl)-acrylamide et leur utilisation comme modulateurs de pak ou nampt |
MA42655A (fr) | 2015-08-18 | 2021-04-07 | Karyopharm Therapeutics Inc | Acrylamide de (s,e)-3-(6-aminopyridin-3-yl)-n-((5-(4-(3-fluoro-3-méthylpyrrolidine-1-carbonyl)phényl)-7-(4-fluorophényl)benzofuran-2-yl)méthyl) pour le traitement du cancer |
US20190002448A1 (en) | 2015-12-31 | 2019-01-03 | Karyopharm Therapeutics Inc. | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof |
WO2017117447A1 (en) | 2015-12-31 | 2017-07-06 | Karyopharm Therapeutics Inc. | Multicyclic compounds and uses thereof |
-
2016
- 2016-08-18 MA MA042655A patent/MA42655A/fr unknown
- 2016-08-18 AU AU2016308829A patent/AU2016308829A1/en not_active Abandoned
- 2016-08-18 EA EA201890524A patent/EA201890524A1/ru unknown
- 2016-08-18 CA CA2995380A patent/CA2995380A1/en not_active Abandoned
- 2016-08-18 CN CN201680060621.6A patent/CN108137563A/zh active Pending
- 2016-08-18 JP JP2018509622A patent/JP2018528196A/ja active Pending
- 2016-08-18 EP EP16756931.8A patent/EP3337797A1/en not_active Withdrawn
- 2016-08-18 US US15/753,897 patent/US10363247B2/en active Active
- 2016-08-18 WO PCT/US2016/047566 patent/WO2017031323A1/en active Application Filing
- 2016-08-18 MX MX2018001979A patent/MX2018001979A/es unknown
-
2018
- 2018-02-08 IL IL257422A patent/IL257422A/en unknown
- 2018-11-15 HK HK18114602.1A patent/HK1255438A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP3337797A1 (en) | 2018-06-27 |
JP2018528196A (ja) | 2018-09-27 |
HK1255438A1 (zh) | 2019-08-16 |
US20180235948A1 (en) | 2018-08-23 |
CN108137563A (zh) | 2018-06-08 |
AU2016308829A1 (en) | 2018-03-08 |
IL257422A (en) | 2018-04-30 |
US10363247B2 (en) | 2019-07-30 |
EA201890524A1 (ru) | 2018-07-31 |
CA2995380A1 (en) | 2017-02-23 |
MA42655A (fr) | 2021-04-07 |
WO2017031323A1 (en) | 2017-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018001979A (es) | (s,e) -3- (6-aminopiridin-3-il) -n- ( (5- (4- (3-fluoruro-3 metilpirrolidin-1-carbonil) fenil) -7- (4 fluorofenil) benzofuran-2-il)metil)acrilamida para el tratamiento del cancer. | |
PH12018502125A1 (en) | Bipyrazole derivatives as jak inhibitors | |
EA201690752A1 (ru) | Ингибиторы g12c kras | |
EA201891191A1 (ru) | 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения | |
MX2016017030A (es) | Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos. | |
EA201991884A3 (ru) | Ингибиторы g12c kras | |
EA201691853A1 (ru) | Агонисты мускариновых рецепторов | |
MX2015011984A (es) | Inhibidores de bromodominio de dihidro-pirrolopiridinona. | |
PH12014501157A1 (en) | Pharmaceutical formulations | |
EA201590228A1 (ru) | Антагонисты 5-ht3 рецептора | |
MX2023000100A (es) | Compuestos diolicos de aminopirazina como inhibidores de fosfoinositida 3-cinasas-gamma. | |
EA201690741A1 (ru) | Составы (s)-3-(4-((4-(морфолинометил)бензил)окси)-1-оксоизоиндолин-2-ил)пиперидин-2,6-диона | |
PH12017500029A1 (en) | 4,5-dihydroisoxazole derivatives as nampt inhibitors | |
EA201692260A1 (ru) | Соединения 1,3,4-тиадиазола и их применение в лечении рака | |
PH12019500568A1 (en) | Dopamine-b-hydroxylase inhibitors | |
NZ720879A (en) | Indazole compounds as 5-ht4 receptor agonists | |
MX2014003455A (es) | Derivados de metanosulfonamida sustituidos con arilo o n-heteroarilo como ligandos de receptor vanilloide. | |
EA201792558A1 (ru) | Противогрибковый 4-(4-(4-(((3r,5r)-5-((1h-1,2,4-триазол-1-ил)метил)-5-(2,4-дифторфенил)тетрагидрофуран-3-ил)метокси)-3-метилфенил)пиперазин-1-ил)-n-(2-гидроксициклогексил)бензамид или его фармацевтически приемлемая соль | |
TW201713630A (en) | Substituted quinazoline compounds and methods of use thereof | |
MX2015015290A (es) | Compuestos furanona como inhibidores de quinasa. | |
CY1122422T1 (el) | Αγωγη της διαταραχης του παροξυσμικου ακραιου πονου | |
MA50899B1 (fr) | Composés utiles pour l'inhibition de cdk7 | |
MY192305A (en) | Bipyrazole derivatives as jak inhibitors | |
EA201990686A1 (ru) | Нафтиридиновые соединения в качестве ингибиторов jak киназы | |
UA110978C2 (uk) | Азетидинілфенілові, піридилові або піразинілкарбоксамідні похідні як інгібітори jak |